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Hirudin N-terminal core domain residues 143 (r-Hir143) were prepared from limited proteolysis of recombinant hirudin by V8 Staphylococcal 
protease followed by purification with reversed-phase HPLC. r-Hir IA3 lacks the putative reactive site of hirudin (Lye’), but binds to thrombin 
(with K, of 300 nM) and blocks the catalytic activity of the protease. The structural element which accounts for the thrombin inhibitory activity 
of r-Hirr” is analyzed in this report. 
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1. INTRODUCTION 
Hirudin is the most potent thrombin-specific in- 
hibitor known [1,2]. This inhibitor was first isolated 
from the leech Hirudo medicinalis [3] and can be now 
produced by recombinant DNA technology [4,5]. The 
exceedingly high binding affinity and specificity of the 
hirudin-thrombin complex has evoked intense interest 
in elucidating their interaction at the molecular level. 
Two domains of hirudin have been identified to bind 
specifically to independent sites of thrombin. The acidic 
C-terminal domain (residues 52-65) has been predicted 
[6] and proven [7,8] to bind to a non-catalytic site of 
thrombin which is required for fibrinogen recognition 
[9,10]. Seven lysyl residues of thrombin were recently 
identified to participate in this recognition site [ 11,121. 
40-48 was suggested to play a role, the composition and 
exact location of this hydrophobic region is not known. 
In this communication, we demonstrate that part of this 
hydrophobic segment is located within the fragment 
containing residues l-43 (r-Hir’ -43). 
2. EXPERIMENTAL 
2.1, Materials 
The N-terminal domain (r-Hir’-s2) blocks the active 
site of thrombin [13]. Within the N-terminal domain, 
there are three lysines (Lys2’, LYS~~ and Lys4’), and 
Lys4’ was thought to be the reactive site [2,6]. Site- 
directed mutagenesis ubsequently confirmed a role for 
Lys4’, but at the same time also demonstrated that its 
contribution to the overall hirudin-thrombin binding 
was marginal. Replacement of Lys4’ by either Gln [14], 
Glu [ 151 or Asn [16] caused only a ten-fold increase of 
the dissociation constant. Indeed the more important 
structural constituent of hirudin which blocks the active 
site region of thrombin appears to be a hydrophobic 
segment which is complementary to an apolar binding 
pocket adjacent to the catalytic center of thrombin 
[ 10,17-l 91. Although the region encompassing residues 
Human alpha-thrombin was purchased from the Center for 
Diagnostic Products (Boston, USA). Recombinant desulfated hirudin 
(CGP-39393) has been produced by Ciba-Geigy in collaboration with 
Platorgan KG (Bad Zwischenahn, FRG) [4] and was kindly provided 
by Dr W. Maerki. N-cr-Acetylated-Hir43-52 (CGP 48389) was kindly 
supplied by Dr H. Rink. Staphylococcus aureus strain V8 protease 
was from Sigma. A monoclonal antibody raised against r-hirudin 
(MAb 4049-83-12) was produced and characterized as described in 
[20]. The substrate tosyl-Gly-Pro-Arg-pNa (Chromozym TH) was 
from Boehringer Mannheim, FRG. 
2.2. Digestion of r-hirudin and r-Hir’-” by V8 protease 
TO prepare r-Hir’-43 , r-hirudin (100,ug) was mixed with 3Opg of V8 
protease in 50 pl of 50 mM ammonium bicarbonate buffer (pH 8.0, 
containing 2 mM EDTA). Digestion was carried out at 37°C for 1 h. 
The proteolytic fragments were separated by reverse-phase HPLC 
with the conditions described in fig.1. For extensive digestion of r- 
Hir’-43 and its oxidized form, the samples were digested with V8 pro- 
tease under similar conditions up to 24 h (with the exception of an en- 
zyme/substrate weight ratio of 1: 10). Ahquots of the time course 
digested sample were removed, freeze-dried and analyzed by quan- 
titative N-terminal analysis to evaluate the extent of digestion at 
Glu*-Serg and Glu”-Gly’* (fig.2). 
2.3. Amino acid analysts and quantitative N-terminal analysk 
Correspondenceaddress: J.-Y. Chang, R-1056,309 Ciba-Geigy Ltd., 
Base1 CH-4002, Switzerland 
Amino acid compositions of hirudin fragments were determined by 
the dimethylaminoazobenzene sulfonyl chloride precolumn deriva- 
tization method 1211. N-terminal amino acids of hirudin fragments 
were quantitatively analyzed by the dimethylaminoazobenzene iso- 
thiocyanate (DABITC) method [22]. 
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2.4. Competitive ELISA assay 
The two-step competitive ELISA, using 96-well microtiter plates 
coated with biotinylated r-hirudin complexed with avidin was describ- 
ed in [20]. 
2.5. Amidoiytic assay of thrombin 
Assays were performed as described previously [23] at 37’C in 0.05 
M Tris-HCl buffer, pH 7.8, containing 0.1 M NaCl and 0.1% po- 
ly(ethylene glycol), M, = 6000. 
3. RESULTS 
3.1. Preparation and characterization of rHir1-43 
When intact hirudin was digested by V8 protease, 
Glu-Xaa bonds at the C-terminal region were preferen- 
tially cleaved, with Gl~~~-Gly~~ being the most suscepti- 
ble linkage [6]. HPLC separation of the hirudin digest 
allowed the N-terminal core domain (r-Hir1-43) to be 
isolated with purity over 99% (fig.1). The purity of r- 
t 
B 
i: 
0 10 20 
min 
Fig.1. HPLC purification of r-HirId4’. (A) Separation by reverse- 
phase HPLC of recombinant hirudin fragments obtained after 1 h 
digestion by VS protease. The peaks were identified by ammo acid 
analysis. 100 ,ug of material was applied to the column. The column 
was Vydac C-18, 5 pm, for peptide and protein. Solvent A was 0.1% 
TFA in water. Solvent B was 0.1% TFA in acetonitrile/water (6:4, 
v/v). There was a linear gradient from 20% to 80% B in 30 min. The 
flow rate was 1 ml/mm. (8) The peak corresponding to r-Hir’-43 was 
collected (from 25 repetitive injections), pooled and rechromato- 
graphed using the same conditions as in (A). 8 fig of material was ap- 
Fig.2. The digestion rate of two Glu-Xaa bonds of r-Hir’-43 by V8 
protease. The intact r-Hir ‘-43 (dashed lines) and performic acid- 
oxidized r-HirIe4’ (solid lines) were digested by V8 protease under 
identical conditions (see text). The digestion rate of Ofus-Ser’ and 
Glut’-Gly’* was evaluated by quantitative N-terminal analysis. The 
plied on the column. recovery of the N-terminal Val was taken as 100%. 
Table 1 
Amino acid composition” of r-Hirlm4’ 
Amino acid Found Expected 
Asp 
GlU 
Ser 
Thr 
GlY 
Ala 
Arg 
Pro 
Valb 
Met 
Be 
Leu 
Phe 
112 CYSC 
Lys 
His 
Tv 
6.23 (6) 
6.80 (7) 
2.95 (3) 
3.22 (3) 
6.76 (7) 
0.10 (0) 
0.17 (0) 
0.06 (0) 
2.70 (4) 
0.08 (0) 
0.71 (1) 
3.26 (3) 
0.08 (0) 
5.90 (6) 
2.10 (2) 
0.13 (0) 
1.04 (1) 
a 1 cg of the sample was hydrolyzed by gas-phase 6 N HCI, dabsylated 
and 50 ng of the derivatized sample was analyzed 
b The lower than expected value of Val is due to incomplete digestion 
of Vat-Val 
’ Quantitatively evaluated as cystine (2.95 residues/mol) 
Hir’-43 was further confirmed by quantitative N- 
terminal analysis (Val, > 99~0) and amino acid analysis 
(table 1). 
r-Hirlv4j retains the compact structure due to the in- 
tactness of the three disulfide bonds. While denatured 
and oxidized r-Hir1-43 was readily digested by V8 pro- 
tease at Glu*-Ser’ and Gl~“-Gly*~ , its intact form was 
hardly digestable even after prolonged incubation 
(fig.2). In an ELISA assay, we have employed a 
monoclonal antibody to examine the cross reactivity of 
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Fig.3. ~m~titive ELISA. Assay of MAb 41349-83-12 binding to in- 
tact recombinant hirudin (-&-), r-Hir’-” (-A-), r-Hir’-43 (0) 
and N-acacetyl-Hir43-‘2 (-o-). B/B, x 100% represents the 
percentage of MAb bound to the plate. 
intact r-hirudin, r-Hirl-“, r-Hir’-43 and i&x-ace- 
tylated-Hir43-52. This antibody (MAb~9-83-12) 
recognizes the epitope of r-hirudin at the region encom- 
passing residues GIu~~ to Lys4’ [20]. The results are 
shown in fig.3. r-Hirudin and r-Hir’-‘* exhibit over 
95% cross-reactivity. The antibody, however, does not 
bind to either r-Hir’-43 or Hir43-52. The latter result in- 
dicates that the conformation of the segment residues 
43-52 within r-Hirre5* cannot be mimicked by synthetic 
peptide. This result is inconsistent with the finding that 
N-cr-acetylated-Hir43-52 did not display appreciable 
thrombin inhibitory activity even at the low micromolar 
concentration (data not shown). 
3.2. The thrombin inhibitory activity of r-Hi#-43 
Initial velocity experiments in which both the 
substrate and r-Hir’-43 were varied established that r- 
Hir’-43 was a competitive inhibitor of thrombin (fig.4). 
These data were fitted by weighted linear regression [24] 
to the equation describing competitive inhibition [25] to 
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Fig.4. Effect of r-Hir’-43 on the amidolytic activity of alpha- 
thrombin. Assays were performed as described in section 2 with the 
tosyI-Gly-Pro-Arg-pNa in the presence of 0 (o), 225 (A), 450 (v) and 
900 (o) nM of r-Hir’-43. The lines represent the best fit of the data to 
the equation for competitive inhibition; the estimates obtained from 
the analysis of the data were: Kcat = 251 f 5 s-‘, Km = 9.1 + 0.4 
aM and Ki = 299 + 12 nM. 
yield an estimate of 299 f 12 nM for the inhibition 
constant (Ki). This value corresponds to a binding 
energy of 38.7 kJ mol-‘. 
4. DISCIJSSION 
We have demonstrated that the N-terminal core do- 
main of hirudin (r-Hir’-43) devoid of the putative reac- 
tive site still possesses thrombin inhibitory activity. r- 
Hir’-43 contains two lysyl residues (Lys*’ and LYS~~), 
however, it is unlikely that these two lysines would con- 
tribute to its interaction with thrombin. Lys*’ and LYS~~ 
are not conserved in about 14 hirudin variants which 
have been sequenced so far (for review, see [26]. 
Replacement of them by either Gln [14], Glu or Ile [15] 
caused no effect on the hirudin-thrombin binding af- 
finity. Thus, the structural element of r-Hir1-43 which 
blocks the active site region of thrombin is most likely 
a hydrophobic cluster which is complement~y to an 
apolar binding pocket of thrombin [IO, 18,191. This 
apolar binding pocket is immediately adjacent to the 
catalytic center of thrombin [lo] and makes a signifi- 
cant contribution towards thrombin’s specificity for 
fibrinogen, tripeptide substrates (e.g. chromoz~ TH) 
and many nonfibrinogen polypeptide substrates [181. 
The specificity of thrombin for fibrinogen is further 
enhanced by an independent fibrinogen recognition site 
of the enzyme. At least 7 lysyl residues within the B- 
chain of thrombin (Lys2*, LY?~, LYS~~, Lys”, Lysro6, 
Lys’ 0’ and LYS’~~) have been identified to be involved in 
this fibrinogen recognition site [ 11,121. 
As compared to r-Hirr -‘* [13], r-Hir”-43 has a 
12-fold increased dissociation constant with thrombin. 
This suggests that residues 43-52 contain some struc- 
tural elements that interact with the active site region of 
thrombin. This is further supported by the observation 
that the monoclonal antibody (MAb 4049-83-12) which 
binds to this domain completely neutralizes the an- 
ticoagulant activity of hirudin [20]. Synthetic peptide 
Ac-Gly-Thr-Pro-Lys-Pro-CONHz (corresponding to 
residues 44-48 of hirudin) was also found to be a 
Fig.5. Structure and functional domain of recombinant hirudin. r- 
Hirr-43 and r-Hir43-“2 contain structural elements which bind to the 
active site region of thrombin. The structural elements which bind to 
the active site region of thrombin are exclusively focated with r- 
His’-“. The structural elements which bind to the fibrinogen recogni- 
tion site of thrombin are exclusively located within r-Hirs2-65. The 
three disulfide linkages (o-+) and three lysyl residues (m) are 
denoted. 
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moderate reversible inhibitor of thrombin with a lui of 
120pM [29]. In addition to Lys4’ as the putative reac- 
tive site, Pro46 and Pro48 may also form part of this 
hydrophobic cluster. In the structure of hirudin 
elucidated by NMR [27,28], Pro46 and Pro4’ are close to 
Val’, Val’ and Tyr3 1271. Chemical modification of the 
N-terming Val was quantitatively protected upon com- 
plexing with thrombin [l 11. Substitution of Val’ and 
Val’ for amino acids other than hydrophobic residues 
caused a marked increase of the hirudin-thrombin 
dissociation constant [30]. Based on these data, it seems 
possible that Val’, Val’, Tyr3, Pro46 and Pro48 are ma- 
jor constituents of a discontiguous hydrophobic site in 
hirudin that accounts for the binding strength of r- 
Hir’-43 and r-Hir1-52 with thrombin. The domains of 
hirudin which have been identified to contribute to the 
hirudin-thrombin complex are summarized in fig.5. 
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